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Abstract 
A 43-year-old woman with drug-related blepharospasm was followed up for 22 months. 
She had undergone etizolam treatment for 19 years for indefinite complaints. We 
examined her cerebral glucose metabolism 5 times (between days 149 and 688 since 
presentation), using positron emission tomography, and identified regions of interest in 
the thalamus, caudate nucleus, putamen, and primary somatosensory area on both sides. 
The severity of the blepharospasm was evaluated by PET scanning using the Wakakura 
classification. Sixteen women (mean age 42.4 ± 11.7 years) were examined as normal 
controls. The thalamic glucose metabolism in our patient was significantly increased on 
days 149, 212, and 688. The severity of the blepharospasm was positively correlated with 
the thalamic glucose metabolism, suggesting that the severity of blepharospasms 
reflects thalamic activity. 
Introduction 
Essential blepharospasm (EB) is a form of focal dystonia characterized by involuntary 
movement of the musculature in the upper face. Several researchers have studied focal 
dystonia using positron emission tomography (PET) and 
18F-fluorodeoxyglucose (
18F-
FDG). Galardi et al. [1] reported hypermetabolism in the thalamus, basal ganglia, anterior 
cingulate gyrus, and cerebellum in patients with spasmodic torticollis, and Esmaeli-
Gutstein et al. [2] found a relative increase in metabolic activity in the thalamus of 
patients with EB. Suzuki et al. [3] have reported glucose hypermetabolism in the thalamus  
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of patients with EB and suggested that dysfunction of the basal ganglia-thalamocortical 
motor circuit may play a major role in the pathophysiology of dystonia. 
We hypothesized that the severity of blepharospasm is correlated to the activity in the 
thalamus or basal ganglia. In the present study, a patient with drug-induced 
blepharospasm was followed up and her cerebral glucose metabolism was recorded 5 
times using PET and 
18F-FDG. We assume that the pathophysiologies of drug-related 
blepharospasm and EB are similar. Glucose metabolism in the thalamus, the basal ganglia, 
and the primary somatosensory area (PSA) were evaluated and the relationship between 
the severity of blepharospasm and glucose metabolism in these areas was analyzed.  
Materials and Methods 
A 43-year-old woman presented with difficulty in opening her eyes (day 0). She had no organic brain 
disorder or other neuropsychiatric disease as evaluated by neurologists using conventional diagnostic 
magnetic resonance imaging (MRI) and no family history of dystonic diseases. She had taken 3 mg/day 
of etizolam for 19 years for the treatment of indefinite complaints, and the blepharospasm had 
developed recently [4]. She received an injection of botulinum-A toxin administered bilaterally to the 
orbicularis oculi on day 72, with unsatisfactory results. However, upon discontinuation of etizolam, her 
symptoms gradually improved in the course of a year. PET scanning was performed 5 times in the 
course of 22 months (on days 149, 212, 310, 443, and 688), and the severity of the spasms at the time of 
PET scanning was evaluated according to the Wakakura classification [5]. 
Sixteen women (mean age, 42.4 ± 11.7 years) were recruited as normal controls, and MRI and 
18F-
FDG PET were performed. Informed consent was obtained from all study participants. The protocol of 
this study was approved by the institutional ethics committee of the Tokyo Metropolitan Institute of 
Gerontology. All the procedures conformed to the tenets of the Declaration of Helsinki. 
MR images were obtained with a 1.5-Tesla Signa Horizon scanner (General Electric, Milwaukee, 
Wisc., USA) in order to register PET and MR images. Transaxial images with T1-weighted contrast 
[3D-SPGR, repetition time (TR) = 9.2 ms, echo time (TE) = 2.0 ms, matrix size = 256 × 256 × 124, voxel 
size = 0.94 × 0.94 × 1.3 mm] and T2-weighted contrast (first spin echo, TR = 3,000 ms, TE = 100 ms, 
matrix size = 256 × 256 × 20, voxel size = 0.7 × 0.7 × 6.5 mm) were obtained. 
PET scans were obtained using the SET 2400W whole-body scanner (Shimadzu, Kyoto, Japan) at the 
Positron Medical Center, Tokyo Metropolitan Institute of Gerontology. Attenuation was corrected by a 
transmission scan with a 
68Ga/
68Ge rotating source. A bolus of 150 MBq 
18F-FDG was injected 
intravenously. The subjects were then requested to lie down comfortably with their eyes closed. A 6-min 
emission scan in the 3D acquisition mode was started 45 min after the injection, and 50 transaxial 
images with an interslice interval of 3.125 mm were obtained. The tomographic images were 
reconstructed using a filtered backprojection method with a Butterworth filter (cutoff frequency: 1.25 
cycles/cm and order of 2). 
PET images were three-dimensionally registered to their 3D-SPGR MR images using the Automated 
Medical Images Registration (AMIR) program [6]. Further data analysis was performed on LINUX 
workstations using the Dr. View program (AJS, Tokyo, Japan). Regions of interest (ROIs), i.e. 8.5-mm-
diameter circles, were defined interactively on the resliced PET images by visual inspection with 
reference to the corresponding MR image. The ROIs were placed over the bilateral thalamus, caudate, 
putamen, and PSA, and the cerebral glucose metabolism in each region was measured. The values of 
cerebral glucose metabolism in the ROIs were normalized according to the global cerebral glucose 
metabolism, which was calculated by averaging voxels >20% of the maximum value. The normalized 
values of glucose metabolism in each area in the patient were compared to the corresponding average 
values in the normal controls, and a difference of 2.5 SD from the controls was considered statistically 
significant. The correlation coefficient between the severity of blepharospasm and the normalized 
glucose metabolism in each area studied was also calculated.  
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The glucose metabolism in the thalamus of the patient was increased significantly on 
days 149 and 212 (table 1). However, a significant change was not observed in the other 
areas (caudate, putamen, and PSA). The severity of the blepharospasm was 3 on day 149, 
2 on day 212, 1 on day 310, 1 on day 443, and 2 on day 688. Regression analyses with the 
data of the bilateral thalamus demonstrated a significant positive correlation between 
cerebral glucose metabolism and the severity of the blepharospasm [correlation 
coefficient (r): right: 0.853 (p < 0.05), left: 0.953 (p < 0.01)] (fig. 1). 
Discussion 
We observed cerebral glucose hypermetabolism in the thalamus of a patient with drug-
related blepharospasm. Reduced cerebral glucose metabolism in the thalamus was found 
to be correlated with an improvement in the blepharospasm. Thus, the activity in the 
thalamus may be related to the severity of blepharospasms. 
Blepharospasm is a dystonic disorder, and there are several reports on cerebral glucose 
hypermetabolism in the thalamus of patients with dystonia [1–3, 7], including our 
previous report. Esmaeli-Gutstein et al. [2] classified blepharospasms on the basis of 
severity (mild, moderate, and severe) in 10 patients and examined the relationship 
between the severity and cerebral glucose metabolism in the thalamus using 
18F-FDG 
PET. They did not find a correlation between glucose metabolism and blepharospasm 
severity in their study, possibly because the interval between the most recent botulinum 
toxin injection and PET was not uniform in each patient. 
Further, Odergren et al. [7] measured cerebral blood flow in four patients with writer’s 
cramp and four controls, using PET. They reported that the perceived difficulty and signs 
of dystonia progressed with the duration of writing, which in turn correlated with 
increased activity in the thalamus of the patients. Many studies have reported thalamic 
hyperactivity in patients with dystonic diseases, but the neurophysiological mechanisms 
of this hyperactivity are not well defined. In our previous study, we observed glucose 
hypermetabolism in the thalamus of EB patients whose spasms were suppressed by 
botulinum toxin treatment [3]. This result may indicate that the hyperactivity in the 
thalamus is caused by the blepharospasm itself.  
On the other hand, the hyperactivity in the thalamus may be secondary to dystonic 
muscle spasms. There are 2 possible explanations for the hyperactivity in the thalamus. 
First, the somatosensory input from the skin induced by dystonic movement may activate 
the basal ganglia-thalamocortical motor circuit. Gobbelé et al. [8] investigated the 
interference of tactile and painful stimuli on thalamocortical processing of somatosensory 
information in humans, using somatosensory evoked potentials. They observed that the 
thalamic source was significantly increased during pain interference. Second, the 
activation of the thalamus may be due to neuronal projection from the muscle spindle 
that contracts with dystonic muscle spasms. Katter et al. [9] observed that the neurons 
that project from the jaw-muscle spindle to the thalamus were activated with 
microelectrodes in the rat. In the present study, we observed a patient who developed 
blepharospasm after long-term etizolam treatment. Wakakura et al. [4] examined 254 
patients with blepharospasm and reported that 13.8% of them had used etizolam before  
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the onset of blepharospasm. They concluded that prolonged use of benzodiazepines or 
thienodiazepines may induce blepharospasm. The clinical features of drug-related 
blepharospasm are similar to those of EB, and the spasms may resolve on discontinuing 
the use of related drugs [4]. In our case, the symptoms of blepharospasm improved to 
some extent after etizolam was discontinued and, thus, the patient’s condition could be 
diagnosed as drug-related blepharospasm. 
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Table 1. Cerebral glucose metabolism in a patient with blepharospasm 
Brain area  Day Severity  R/L 
thalamus caudate  putamen PSA 
149 3  R 1.64* 1.28  1.46  1.20 
   L  1.66* 1.24  1.44  1.15 
212 2  R 1.57* 1.39  1.46  1.18 
   L  1.63* 1.43  1.47  1.12 
310  1  R  1.52 1.45 1.53 1.23 
   L  1.51 1.33 1.39 1.25 
443  1  R  1.49 1.31 1.44 1.13 
   L  1.52 1.45 1.42 1.14 
688  2  R  1.52 1.41 1.48 1.17 
   L  1.56 1.43 1.44 1.18 
Normal average  R  1.37±0.07  1.41±0.08  1.51±0.14  1.15±0.07 
  L  1.37±0.08 1.41±0.09 1.51±0.12 1.15±0.06 
Values indicate glucose metabolism in the ROIs, as normalized 
according to the global cerebral glucose metabolism.  
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Fig. 1. Images of PET with 
18F-FDG in a patient with blepharospasm on days 149 (left) and 443 (right) 
after presentation. The severity of the blepharospasm was 3 on day 149 and 1 on day 443. The glucose 
metabolism in the thalamus was high on day 149 and low on day 443 (arrows). 
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